OBJECTIVE: Advanced glycation end products (AGEs) are modifiable risk factors for renal disease that were primarily studied in persons with diabetes or endstage renal disease. Our objective was to characterize the relationship between AGEs and renal function in community-dwelling adults. DESIGN: The presence of serum L-carboxymethyl-lysine (CML), a dominant AGE, was compared with renal function in a cross-sectional analysis. SETTING: This study was part of the Baltimore Longitudinal Study of Aging in Baltimore, Maryland. PATIENTS OR OTHER PARTICIPANTS: Participants included community-dwelling men and women, aged 26 to 93 years, seen during a regular follow-up visit to the Baltimore Longitudinal Study of Aging between 2002 and 2007. MAIN OUTCOME MEASURES: The main outcome measures included chronic kidney disease (CKD) at stage >/=3 of the National Kidney Foundation classification (estimated glomerular filtration rate [eGFR] of<60 mL/minute/1.73 m(2)) and eGFR. RESULTS: Of 750 adults, 121 (16.1%) had CKD. Serum CML was associated with CKD (odds ratio expressed per one standard deviation, 1.37; 95% confidence interval, 1.11 to 1.67; P=.003) in a multivariate logistic regression model adjusting for age, race, smoking, and chronic diseases. Serum CML was associated with eGFR (mL/minute/1.73 m(2)) (beta=-2.21, standard error=0.57, P=.0001) in a multivariate linear regression model, adjusting for age, race, smoking, and chronic diseases. After excluding patients with diabetes, serum CML was associated with CKD (odds ratio per one standard deviation, 1.38; 95% confidence interval, 1.12 to 1.70; P=.003) and eGFR (beta=-2.09, standard error=0.59, P=.0005), adjusting for the same covariates. CONCLUSION: Serum CML, a dominant AGE, is independently associated with CKD and eGFR. Copyright (c) 2010 National Kidney Foundation, Inc. All rights reserved.
OBJECTIVE: Advanced glycation end products (AGEs) are modifiable risk factors for renal disease that were primarily studied in persons with diabetes or endstage renal disease. Our objective was to characterize the relationship between AGEs and renal function in community-dwelling adults. DESIGN: The presence of serum L-carboxymethyl-lysine (CML), a dominant AGE, was compared with renal function in a cross-sectional analysis. SETTING: This study was part of the Baltimore Longitudinal Study of Aging in Baltimore, Maryland. PATIENTS OR OTHER PARTICIPANTS: Participants included community-dwelling men and women, aged 26 to 93 years, seen during a regular follow-up visit to the Baltimore Longitudinal Study of Aging between 2002 and 2007. MAIN OUTCOME MEASURES: The main outcome measures included chronic kidney disease (CKD) at stage >/=3 of the National Kidney Foundation classification (estimated glomerular filtration rate [eGFR] of<60 mL/minute/1.73 m(2)) and eGFR. RESULTS: Of 750 adults, 121 (16.1%) had CKD. Serum CML was associated with CKD (odds ratio expressed per one standard deviation, 1.37; 95% confidence interval, 1.11 to 1.67; P=.003) in a multivariate logistic regression model adjusting for age, race, smoking, and chronic diseases. Serum CML was associated with eGFR (mL/minute/1.73 m(2)) (beta=-2.21, standard error=0.57, P=.0001) in a multivariate linear regression model, adjusting for age, race, smoking, and chronic diseases. After excluding patients with diabetes, serum CML was associated with CKD (odds ratio per one standard deviation, 1.38; 95% confidence interval, 1.12 to 1.70; P=.003) and eGFR (beta=-2.09, standard error=0.59, P=.0005), adjusting for the same covariates. CONCLUSION: Serum CML, a dominant AGE, is independently associated with CKD and eGFR. Copyright (c) 2010 National Kidney Foundation, Inc. All rights reserved.
Authors: D A Kass; E P Shapiro; M Kawaguchi; A R Capriotti; A Scuteri; R C deGroof; E G Lakatta Journal: Circulation Date: 2001-09-25 Impact factor: 29.690
Authors: Thorsten P Degenhardt; Nathan L Alderson; David D Arrington; Robert J Beattie; John M Basgen; Michael W Steffes; Suzanne R Thorpe; John W Baynes Journal: Kidney Int Date: 2002-03 Impact factor: 10.612
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Mohammed E Suliman; Olof Heimbürger; Peter Bárány; Björn Anderstam; Roberto Pecoits-Filho; Ernesto Rodríguez Ayala; A Rashid Qureshi; Ingela Fehrman-Ekholm; Bengt Lindholm; Peter Stenvinkel Journal: J Am Soc Nephrol Date: 2003-06 Impact factor: 10.121
Authors: Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer Journal: Artif Organs Date: 2013-11-11 Impact factor: 3.094
Authors: Karen A Weikel; Paul Fitzgerald; Fu Shang; M Andrea Caceres; Qingning Bian; James T Handa; Alan W Stitt; Allen Taylor Journal: Invest Ophthalmol Vis Sci Date: 2012-02-02 Impact factor: 4.799
Authors: V C Luft; B B Duncan; M I Schmidt; L E Chambless; J S Pankow; R C Hoogeveen; D J Couper; G Heiss Journal: Diabet Med Date: 2015-10-06 Impact factor: 4.359
Authors: Jovia L Nierenberg; Jiang He; Changwei Li; Xiaoying Gu; Mengyao Shi; Alexander C Razavi; Xuenan Mi; Shengxu Li; Lydia A Bazzano; Amanda H Anderson; Hua He; Wei Chen; Jason M Kinchen; Casey M Rebholz; Josef Coresh; Andrew S Levey; Lesley A Inker; Michael Shlipak; Tanika N Kelly Journal: Metabolomics Date: 2019-11-13 Impact factor: 4.290
Authors: Nilam S Mangalmurti; Shampa Chatterjee; Guanjun Cheng; Emily Andersen; Aishat Mohammed; Donald L Siegel; Ann Marie Schmidt; Steven M Albelda; Janet S Lee Journal: Transfusion Date: 2010-11 Impact factor: 3.157